Abstract：
OBJECTIVE: The most prevalent lacrimal apparatus dysfunctions associated with differentiated thyroid cancer(DTC) after I-131 therapy are dry eye and nasolacrimal duct obstruction(NLDO), leading to ocular discomfort and lower quality of life for patients. It is crucial to diagnose and manage lacrimal apparatus dysfunction associated with I-131 therapy for DTC. Therefore, this review aims to comprehensively summarize and analyze the advances in mechanisms and therapeutic options underlying lacrimal apparatus dysfunction induced by I-131 therapy for DTC.
METHODS: A comprehensive search of CNKI, PubMed, and Wed of Science was performed from the database to December of 2023. Key search terms were \"Thyroid cancer\", \"I-131\", \"Complications\", \"Dry eye\", \"Epiphora\", \"Tear\", \"Nasolacrimal duct\" and \"NLDO\".
RESULTS: The research indicates that I-131 therapy for DTC causes damage to the lacrimal glands and nasolacrimal duct system, resulting in symptoms such as dry eye, epiphora, and mucoid secretions. Moreover, recent research has focused on exploring relevant risk factors of the condition and experimental and clinical treatments. However, there is some controversy regarding the mechanisms involved, whether it is due to the passive flow of I-131 in tears, active uptake of I-131 by the sodium-iodide symporter (NIS) in the lacrimal sac and nasolacrimal duct, or secondary metabolic and hormonal disturbances caused by I-131.
CONCLUSIONS: It is crucial for early detection and preventive measures by ophthalmologists and the need for further studies to elucidate the mechanisms underlying the disease.
METHODS: A comprehensive search of CNKI, PubMed, and Wed of Science was performed from the database to December of 2023. Key search terms were \"Thyroid cancer\", \"I-131\", \"Complications\", \"Dry eye\", \"Epiphora\", \"Tear\", \"Nasolacrimal duct\" and \"NLDO\".
RESULTS: The research indicates that I-131 therapy for DTC causes damage to the lacrimal glands and nasolacrimal duct system, resulting in symptoms such as dry eye, epiphora, and mucoid secretions. Moreover, recent research has focused on exploring relevant risk factors of the condition and experimental and clinical treatments. However, there is some controversy regarding the mechanisms involved, whether it is due to the passive flow of I-131 in tears, active uptake of I-131 by the sodium-iodide symporter (NIS) in the lacrimal sac and nasolacrimal duct, or secondary metabolic and hormonal disturbances caused by I-131.
CONCLUSIONS: It is crucial for early detection and preventive measures by ophthalmologists and the need for further studies to elucidate the mechanisms underlying the disease.
摘要：
目的：I-131治疗后与分化型甲状腺癌（DTC）相关的最常见的泪器功能障碍是干眼和鼻泪管阻塞（NLDO），导致患者眼部不适和生活质量下降。诊断和管理与I-131治疗DTC相关的泪器功能障碍至关重要。因此,本文旨在全面总结和分析I-131治疗DTC导致泪器功能障碍的机制和治疗方案的进展。
方法：CNKI综合检索，PubMed,和WedofScience从数据库中进行到2023年12月。关键搜索词是\"甲状腺癌\",\"I-131\",“并发症”，\"干眼\",\"Epiphora\",\"眼泪\",“鼻泪管”和“NLDO”。
结果：研究表明，I-131治疗DTC会对泪腺和鼻泪管系统造成损害，导致干眼症等症状，顿唇,还有粘液分泌物.此外，最近的研究集中在探索疾病的相关危险因素以及实验和临床治疗。然而,关于所涉及的机制存在一些争议，无论是由于I-131在眼泪中的被动流动，泪囊和鼻泪管中的钠碘转运体（NIS）主动摄取I-131，或由I-131引起的继发性代谢和激素紊乱。
结论：眼科医生的早期发现和预防措施至关重要，并且需要进一步研究以阐明该疾病的潜在机制。
方法：CNKI综合检索，PubMed,和WedofScience从数据库中进行到2023年12月。关键搜索词是\"甲状腺癌\",\"I-131\",“并发症”，\"干眼\",\"Epiphora\",\"眼泪\",“鼻泪管”和“NLDO”。
结果：研究表明，I-131治疗DTC会对泪腺和鼻泪管系统造成损害，导致干眼症等症状，顿唇,还有粘液分泌物.此外，最近的研究集中在探索疾病的相关危险因素以及实验和临床治疗。然而,关于所涉及的机制存在一些争议，无论是由于I-131在眼泪中的被动流动，泪囊和鼻泪管中的钠碘转运体（NIS）主动摄取I-131，或由I-131引起的继发性代谢和激素紊乱。
结论：眼科医生的早期发现和预防措施至关重要，并且需要进一步研究以阐明该疾病的潜在机制。
